Feature | April 08, 2014

GE Healthcare Receives FDA for Q.Clear PET/CT Technology

Technology can enable clinicians to assess patient's response to treatment accurately

GE Healthcare Q.Clear Technology PET/CT Systems Nuclear Imaging

April 8, 2014 — GE Healthcare received U.S. Food and Drug Administration (FDA) 510(k) clearance of its Q.Clear technology, which is designed to provide up to two times improvement in both quantitative accuracy and image quality in PET/CT imaging. 

Over the last decade, positron emission tomography (PET) image reconstruction technology has been designed to provide better image quality, reduced acquisition time and lower injected dose. Current PET iterative reconstruction technologies, such as time of flight (TOF) and OSEM, force a compromise between image quality and quantitation. GE Healthcare said its Q.Clear technology brings convergence to PET imaging without the need for compromise between quantitation and image quality.

"Q.Clear is a major step forward because it can give us a consistent and reliable measurement when determining whether the current course of a patient's cancer treatment is effective," said Dr. Gustav von Schulthess, nuclear medicine chair at University Hospital Zurich. "It will give the oncologist more confidence because if a change of therapy is needed, you want accurate information early on to best adjust treatment for the patient."

Clinicians not only want the ability to detect smaller lesions, but the ability to determine earlier whether the patient is responding to current treatment. Q.Clear aims to help in both areas by providing better quantitation accuracy for truly personalized medicine. Coupled with Q.Suite, which introduced the importance of eliminating variability such as respiratory motion, Q.Clear can enable clinicians to assess treatment response accurately.

"We know that approximately 70 percent of cancer patients don't always respond to their initial course of treatment," said Steve Gray, president and CEO of GE Healthcare MICT. "If we can give clinicians an accurate, reliable, and faster tool to confirm that a change in treatment is needed, the patient will benefit greatly. For example, PET/computed tomography (CT) can help clinicians determine whether chemotherapy is working in fewer cycles, saving patients unnecessary procedures.  Q.Clear gives clinicians the ability to help make that determination."

GE said the system may not be available for sale in all regions. For countries that require CE marking, Q.Clear is not yet CE marked.

For more information: www3.gehealthcare.com

Related Content

Technology | Cardiac Imaging| May 18, 2016
May 18, 2016 — The Intersocietal Accreditation Commission (IAC) recently announced its launch of the IAC QI Self-Asse
News | Radiopharmaceuticals and Tracers| May 13, 2016
NorthStar Medical Radioisotopes LLC is enhancing its production operations at the University of Missouri Research...
GE Healthcare, general purpose digital SPECT/CT, Discovery NM/CT 670 CZT, Barnes-Jewish Hospital, first U.S. install
News | SPECT-CT| May 05, 2016
Doctors and researchers at Barnes-Jewish Hospital and Washington University in St. Louis may be able to better diagnose...
UltraSPECT, 10th anniversary, WBR technology, Wide Beam Reconstruction, FDA approval, nuclear imaging
News | Nuclear Imaging| April 21, 2016
UltraSPECT Inc. announced the 10th anniversary of the U.S. Food and Drug Administration (FDA) approval of its Wide Beam...
PET/CT scan, brain stress center, heart disease predictor, ACC.16
News | PET-CT| April 05, 2016
New research shows individuals with a greater degree of activity in the stress center of the brain also have more...
UltraSPECT, 450th U.S. installation, Firelands Regional Medical Center, nuclear medicine, radiation safety
News | Nuclear Imaging| January 27, 2016
UltraSPECT Inc. has marked the 450th U.S. installation of its low-dose image processing technology for nuclear medicine...
Siemens, Biograph Horizon PET CT, FDA clearance
Technology | PET-CT| January 21, 2016
Siemens Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Biograph...
GE Healthcare, molecular imaging, PET/CT, Discovery IQ, Discovery NM/CT 670 Pro, RSNA 2015

Discovery IQ PET/CT scanner image courtesy of GE Healthcare

News | Nuclear Imaging| November 16, 2015
GE Healthcare’s Molecular Imaging business will showcase the Discovery IQ positron emission tomography/computed...
blood clot detection, single scan, rats, radionuclides, Peter Caravan, whole body

The whole body of a rat can be imaged for blood clots with one PET scan (which is overlaid here on an MRI image) using the FBP8 probe. Arrow points to a blood clot. Image courtesy of Peter Caravan, Ph.D.

News | PET Imaging| September 23, 2015
September 23, 2015 — New research de
Overlay Init